John Valliant, Chief Executive Officer at Fusion Pharmaceuticals Inc. (FUSN), sold 4,800 shares at $7.50 ($36K) on 2022-03-23, disclosed to the SEC on 2022-03-24.
Scheduled sale ($36k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.46 | 700 | $5K | 14.5% |
| 2 | $7.53 | 4,000 | $30K | 83.5% |
| 3 | $7.50 | 100 | $750 | 2.1% |
| Total | $7.52 avg | 4,800 | $36K | 100% |
| Filing → |
| FUSN | SELL | 2022-04-13 | $432K | — | Filing → |
| FUSN | SELL | 2022-04-08 | $16K | — | Filing → |
| FUSN | SELL | 2022-04-05 | $29K | — | Filing → |